External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>PYC announced a $146m capital raise to fund mid/late stage trials in Retinitis Pigmentosa 11 (RP11), expected to enter Phase III this year, and Autosomal Dominant Optic Atrophy (ADOA), as well as early stage studies in Polycystic Kidney Disease (PKD).</li><li>This funds major development across the three current clinical programs, and entry into the clinic for PYC-002 (currently preclinical) in Phelan McDermid Syndrome (PMS).</li><li>This action comes as no surprise; the company reported a remaining 2-3 quarters of cash at its 4C (last note here), although the quantum of the raise was higher than we anticipated.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC announced a $146m capital raise to fund mid/late stage trials in Retinitis Pigmentosa 11 (RP11), expected to enter Phase III this year, and Autosomal Dominant Optic Atrophy (ADOA), as well as early stage studies in Polycystic Kidney Disease (PKD).This funds major development across the three current clinical programs, and entry into the clinic for PYC-002 (currently preclinical) in Phelan McDermid Syndrome (PMS).This action comes as no surprise; the company reported a remaining 2-3 quarters of cash at its 4C (last note here), although the quantum of the raise was higher than we anticipated.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - $146m Capital Raise Removes Funding Overhang